Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection
- PMID: 21192802
- PMCID: PMC3022836
- DOI: 10.1186/1471-2334-10-363
Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection
Abstract
Background: Oral vancomycin (125 mg qid) is recommended as treatment of severe Clostridium difficile infection (CDI). Higher doses (250 or 500 mg qid) are sometimes recommended for patients with very severe CDI, without supporting clinical evidence. We wished to determine to what extent faecal levels of vancomycin vary according to diarrhoea severity and dosage, and whether it is rational to administer high-dose vancomycin to selected patients.
Methods: We recruited hospitalized adults suspected to have CDI for whom oral vancomycin (125, 250 or 500 mg qid) had been initiated. Faeces were collected up to 3 times/day and levels were measured with the AxSYM fluorescence polarization immunoassay.
Results: Fifteen patients (9 with confirmed CDI) were treated with oral vancomycin. Patients with ≥ 4 stools daily presented lower faecal vancomycin levels than those with a lower frequency. Higher doses of oral vancomycin (250 mg or 500 mg qid) led to consistently higher faecal levels (> 2000 mg/L), which were 3 orders of magnitude higher than the MIC90 of vancomycin against C. difficile. One patient receiving 125 mg qid had levels below 50 mg/L during the first day of treatment.
Conclusions: Faecal levels of vancomycin are proportional to the dosage administered and, even in patients with increased stool frequency, much higher than the MIC90. Patients given the standard 125 mg qid dosage might have low faecal levels during the first day of treatment. A loading dose of 250 mg or 500 mg qid during the first 24-48 hours followed by the standard dosage should be evaluated in larger studies, since it might be less disruptive to the colonic flora and save unnecessary costs.
Figures


Similar articles
-
Impact of vancomycin faecal concentrations on clinical and microbiological outcomes in Clostridium difficile infection.Int J Antimicrob Agents. 2015 Aug;46(2):205-8. doi: 10.1016/j.ijantimicag.2015.03.016. Epub 2015 May 30. Int J Antimicrob Agents. 2015. PMID: 26055927 Clinical Trial.
-
Minimal systemic and high faecal exposure to cadazolid in patients with severe Clostridium difficile infection.Int J Antimicrob Agents. 2015 Nov;46(5):576-81. doi: 10.1016/j.ijantimicag.2015.07.015. Epub 2015 Sep 3. Int J Antimicrob Agents. 2015. PMID: 26419191 Clinical Trial.
-
Randomized Controlled Trial of Oral Vancomycin Treatment in Clostridioides difficile-Colonized Patients.mSphere. 2021 Jan 13;6(1):e00936-20. doi: 10.1128/mSphere.00936-20. mSphere. 2021. PMID: 33441409 Free PMC article. Clinical Trial.
-
Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection.Am J Health Syst Pharm. 2012 Jun 1;69(11):933-43. doi: 10.2146/ajhp110371. Am J Health Syst Pharm. 2012. PMID: 22610025 Review.
-
Diagnosis and management of Clostridium difficile infection.Clin Gastroenterol Hepatol. 2013 Oct;11(10):1216-23; quiz e73. doi: 10.1016/j.cgh.2013.03.016. Epub 2013 Mar 28. Clin Gastroenterol Hepatol. 2013. PMID: 23542332 Review.
Cited by
-
Management of Clostridioides difficile colitis: insights for the gastroenterologist.Therap Adv Gastroenterol. 2019 May 6;12:1756284819847651. doi: 10.1177/1756284819847651. eCollection 2019. Therap Adv Gastroenterol. 2019. PMID: 31105766 Free PMC article. Review.
-
Treatment of Clostridium difficile infection in mice with vancomycin alone is as effective as treatment with vancomycin and metronidazole in combination.BMJ Open Gastroenterol. 2015 Nov 2;2(1):e000038. doi: 10.1136/bmjgast-2015-000038. eCollection 2015. BMJ Open Gastroenterol. 2015. PMID: 26568840 Free PMC article.
-
High-resolution fecal pharmacokinetic modeling in mice with orally administered antibiotics.Sci Rep. 2025 Jul 8;15(1):24441. doi: 10.1038/s41598-025-10293-7. Sci Rep. 2025. PMID: 40628921 Free PMC article.
-
Functional genetics of human gut commensal Bacteroides thetaiotaomicron reveals metabolic requirements for growth across environments.Cell Rep. 2021 Mar 2;34(9):108789. doi: 10.1016/j.celrep.2021.108789. Cell Rep. 2021. PMID: 33657378 Free PMC article.
-
A Vancomycin HPLC Assay for Use in Gut Microbiome Research.Microbiol Spectr. 2022 Jun 29;10(3):e0168821. doi: 10.1128/spectrum.01688-21. Epub 2022 May 10. Microbiol Spectr. 2022. PMID: 35536037 Free PMC article.
References
-
- Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, Bourgault AM, Nguyen T, Frenette C, Kelly M. et al.A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353:2442–2449. doi: 10.1056/NEJMoa051639. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical